Drug Profile
Docetaxel prodrugs - Aphios
Alternative Names: Docetaxel-based polymer nanospheres - Aphios; Taxotere® Prodrug - Aphios; Taxotere®-MAb Prodrug - AphiosLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aphios Corporation
- Class Monoclonal antibodies
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Ovarian cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in USA (PO, Controlled release)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (PO, Controlled release)
- 22 Jun 2009 Docetaxel prodrugs - Aphios is available for licensing as of 22 Jun 2009. http://www.aphios.com/